Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 1.00 |
| ▸ | PNMT | P11086 | 1/20 | 0.63 |
| ▸ | RXRA | P19793 | 1/20 | 0.63 |
| ▸ | RXRB | P28702 | 1/20 | 0.63 |
| ▸ | RXRG | P48443 | 1/20 | 0.63 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | DHFR | P00374 | 1/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 1/20 | 0.58 |
| ▸ | AGXT | P21549 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12517046 | 0.88 | MAOB (0.79) | MAOBPNMTRXRARXRBRXRG | |
| Hydrochloric Acid SCHEMBL7429625 | 0.87 | MAOB (1.00) | MAOBRXRARXRBRXRGMAOA | |
| SCHEMBL1586635 | 0.86 | MAOB (0.76) | MAOBPNMTRXRARXRBRXRG | |
| SCHEMBL9627120 | 0.86 | MAOB (0.76) | MAOBRXRARXRBRXRGMAOA | |
| SCHEMBL23004585 | 0.85 | MAOB (0.73) | MAOBRXRARXRBRXRGMAOA | |
| SCHEMBL8414617 | 0.85 | MAOB (0.73) | MAOBRXRARXRBRXRGMAOA | |
| SCHEMBL9626627 | 0.85 | MAOB (0.73) | MAOBRXRARXRBRXRGMAOA | |
| SCHEMBL30398136 | 0.85 | MAOB (0.73) | MAOBRXRARXRBRXRGMAOA | |
| SCHEMBL30397454 | 0.85 | MAOB (0.73) | MAOBRXRARXRBRXRGMAOA | |
| SCHEMBL4417319 | 0.85 | MAOB (0.73) | MAOBRXRARXRBRXRGMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195999-A1 | NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND | NAKAMOTO KAZUTAKA | 2011-08-11 | — | — | US | disclosed |
| US-20110195999-A1 | NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND | NAKAMOTO KAZUTAKA | 2011-08-11 | — | — | US | disclosed |
| US-20110195999-A1 | NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND | NAKAMOTO KAZUTAKA | 2011-08-11 | — | — | US | disclosed |
| US-7932272-B2 | Antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932272-B2 | Antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932272-B2 | Antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20090227799-A1 | Novel Antimalarial Agent Containing Heterocyclic Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1782811-A1 | NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-05-09 | — | — | EP | disclosed |
| EP-1669348-A1 | NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 2006-06-14 | — | — | EP | disclosed |
| US-5912242-A | ANTIEPILEPTIC, ANTI-PARKINSON, ANTIDEPRESSANT, ANTISPASMODIC, NEUROPROTECTIVE OR HYPNOTIC AGENTS, FOR TREATMENT OF NEURODEGENERATIVE DISEASES | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195999-A1 | NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND | ERG28, CYP51A1, XPO1 | MAOB 1175/4885PNMT 3150/4885RXRA 3025/4885 |
| US-20090227799-A1 | Novel Antimalarial Agent Containing Heterocyclic Compound | XPO1, THPO, G6PD | MAOB 2220/4885PNMT 2882/4885RXRA 1892/4885 |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | ERG28, DPM1, CYP51A1 | MAOB 1205/4885PNMT 2872/4885RXRA 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.